Benzinga | Mar 11, 2021 07:30AM EST

SVB Leerink Maintains Outperform on Affimed, Raises Price Target to $14

SVB Leerink analyst Daina Graybosch maintains Affimed (NASDAQ:AFMD) with a Outperform and raises the price target from $9 to $14.